Enable JavaScript to visit this website.

MenB Facts


MenB is a bacterial infection that attacks the brain and spinal cord, and it can also cause an infection of the blood1
Breezy Mom Sitting
Help protect your teen against MenB

There are 5 primary types of bacteria that cause meningococcal disease and for which vaccines are available in the US: A, C, W, Y, and B.7

Even if your teen received a meningococcal meningitis vaccine (MCV4), which covers meningitis A, C, W, and Y, they may be unprotected against MenB. Be sure they get both vaccines and help protect your teen.2

TRUMENBA helps provide protection against MenB.6

Learn more about TRUMENBA

Know the causes and effects of MenB

MenB can be spread through typical teen sharing behaviors1,8-10
Kissing Kissing
Close-quartered living Close-quartered living

Sharing things like drinks and utensils, and kissing, can spread the bacteria that cause MenB. Activities that involve close contact, like communal living or participation in sports teams or other group activities, can also put adolescents and young adults at increased risk.1,8-10

Early symptoms may seem like the flu, but symptoms may progress1,4

Some common symptoms include fever, headache, stiff neck, rash, and confusion.4 You or your teen may not realize that they have a serious infection until it is too late.4 Be sure to help protect your teen by vaccinating with TRUMENBA.6

Potentially deadly or debilitating consequences4,14,15

Approximately 20% of survivors may be affected by significant long-term or permanent consequences.14

The CDC recommends vaccination for types A, C, W, and Y at ages 11 to 12, and a booster at age 16. The CDC-preferred age for MenB vaccination is 16 to 18 years2,11

Meet Meningitis Survivors

Meet Rayna, Katelyn, and Lauren, real survivors who would like to share their experience and how it taught them the importance of getting vaccinated against MenB.

Choose a video
School Kit
TRUMENBA vaccination on campus5,12

TRUMENBA was used in mass vaccination efforts against meningitis B outbreaks at Providence College and the University of Oregon in 2015.

In the US, only less than 10% of 16 to 18 year olds have been vaccinated against MenB.13

pharmacy icon

Want to know where you can get TRUMENBA near you?

Find a location
locator icon
Already received the first dose of TRUMENBA?

Get text reminders for the next dose.

Enroll now
  • Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
  • Some individuals with weakened immune systems may have a reduced immune response
  • Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections
  • Fainting can occur in association with administration of injectable vaccines, including Trumenba
  • The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your health care provider if you are pregnant, or plan to become pregnant
  • Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed
Call 1-844-TRUMENBA (878-6362), 9 AM to 7 PM ET, Monday through Friday, for more information.

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

This product information provided in this site is intended only for residents of the United States. The products discussed in this site may have different product labeling in different countries.

The health information in this site is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

  1. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated April 9, 2018. Accessed August 21, 2018.
  2. MacNeil JR, Rubin L, Folaranmi T. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171-1176.
  3. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: a report by the National Foundation for Infectious Diseases. http://www.nfid.org/meningococcal-b. Published May 2014. Accessed August 21, 2018.
  4. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  5. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607.
  6. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc; 2019.
  7. McNeil LK, Zagursky RJ, Lin SL, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77(2):234-252.
  8. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450.
  9. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century–an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(3):1-9.
  10. Ewald AJ, McKeag DB. Meningitis in the athlete. Curr Sports Med Rep. 2008;7(1):22-27.
  11. Centers for Disease Control and Prevention. Recommended immunization schedule for children and adolescents aged 18 years or younger, UNITED STATES, 2018. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Updated January 1, 2018. Accessed August 21, 2018.
  12. McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak–Oregon, 2015-2016. J Infect Dis. 2017;216(9);1130-1140.
  13. Data on file. Pfizer Inc, New York, NY.
  14. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25.
  15. Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence; prospective, matched-cohort study. Pediatrics. 2009;123(3):e502-e509.
Back to top